A large analysis of data from 17 clinical trials of two high-profile drugs, which were previously presented as a true breakthrough in the fight against Alzheimer's disease, revealed their inability to significantly slow cognitive decline and improve patients' quality of life.
In light of recent research, the seemingly revolutionary drugs for treating Alzheimer's disease may not be as effective as initially thought. An analysis of data from 17 clinical trials of two drugs showed that they do not provide a noticeable improvement in cognitive functions. Researchers concluded that donanemab and lecanemab failed to significantly enhance the quality of life for individuals suffering from dementia.
However, not everyone agrees with these findings. Some experts in the field of Alzheimer's research have already criticized the presented analysis, calling it methodologically unsound. This debate highlights the complexity and ambiguity of approaches to treating neurodegenerative diseases.
Mechanism of Action and Hopes
The drugs in question target beta-amyloid—a sticky substance that accumulates in the intercellular space of the brain in Alzheimer's disease. Scientists have developed specific antibodies to detect and remove this amyloid, similar to how the immune system fights infections. For a long time, this approach yielded no results, causing some disappointment.
Nevertheless, trials of donanemab and lecanemab demonstrated for the first time the ability to slow the decline of cognitive functions. This achievement was seen as a true breakthrough, as it was the first time a medication could influence the destructive process in the brain associated with Alzheimer's disease. The global community placed enormous hopes on these drugs.
Verdict of the Cochrane Collaboration
The international non-profit network of researchers, Cochrane Collaboration, conducted a comprehensive analysis. They examined 17 studies involving over 20,000 volunteers testing seven different drugs aimed at removing amyloid from the brain. Their findings were quite sobering.
The scientists confirmed that these drugs do indeed slow the progression of the disease, but the degree of this slowing was found to be insignificant for patients. Moreover, the use of these drugs is associated with serious risks, including brain swelling and hemorrhages. Furthermore, treatment requires regular injections every two to four weeks and is quite expensive.
Expert Opinion
Professor of neurobiology Edo Richard from Radboud University Medical Center, one of the report's authors, works daily with patients suffering from dementia. When asked by the BBC what he would advise his patients, Richard stated plainly: "I would tell them: 'I think these drugs are unlikely to help you, and they will be a heavy [financial] burden for you and your family.'"
The National Health Service (NHS) in the UK is currently not purchasing or offering these drugs. A treatment course at a private clinic lasting 18 months can cost around £90,000 (approximately $121,000). Richard emphasized the importance of honest communication with patients to avoid giving them false hope.
Paths Forward and Criticism
Professor Richard urges a focus on exploring other treatment methods for Alzheimer's disease. He considers promising the direction aimed at addressing inflammatory processes in the brain. This could open new horizons in the fight against the ailment.
The report's results found support among long-time critics of the amyloid hypothesis. Professor Robert Howard from University College London (UCL) called it "sad and unfair" that these drugs were marketed "without sufficient scientific justification, creating false hopes."
However, the methodology of the Cochrane Collaboration itself has sparked lively discussions within the scientific community. Many experts point to significant differences in the mechanisms of action of each drug, deeming it unfair to group old experimental drugs with new ones that have already proven their effectiveness.
The researchers who conducted the analysis insist that all the drugs they reviewed are aimed at removing amyloid from the brain. Thus, their report is intended to assess the effectiveness of this common approach to treating Alzheimer's disease.
